iShares Biotechnology ETF (IBB)
Market Price (8/11/2026): $200.03
iShares Biotechnology ETF (IBB)
Market Price (8/11/2026): $200.03
Key Takeaways
- IBB has returned +18.6% YTD vs +13.7% for SPY; +51.8% over the past 12 months (SPY +22.3%). details →
- Priced in gold, IBB has returned -30.6% over the past 3 years, vs +56.9% in dollars — its dollar gains have lagged gold. details →
- Over the past month, IBB has seen net inflows of +$157M (+1.7% of assets). details →
- 56% of IBB's portfolio (by weight) is currently profitable, vs 98% for SPY. details →
- IBB is trading at an all-time high. details →
Asset Allocation with IBB
Valuation & Yield
| Forward [4,5] | Now | Historical (CYE & TTM) | |||||
|---|---|---|---|---|---|---|---|
| 8/31/27 | 8/11/26 | 2025 | 2024 | 2023 | 2022 | 2021 | |
| Share Price CYE | $200.02 | $168.65 | $131.78 | $135.03 | $130.14 | $150.78 | |
| Dividend/Share TTM | $0.39 | $0.39 | $0.39 | $0.35 | $0.41 | $0.32 | |
Valuation [1] | |||||||
| P/S | 6.34 | 7.26 | 6.77 | 5.78 | 6.32 | 6.19 | 7.62 |
| P/E | 26.12 | 23.02 | 27.45 | 25.42 | 17.90 | 16.26 | |
| P/E (Non-GAAP) [2] | 27.58 | 35.17 | 28.06 | 30.55 | 61.23 | 22.45 | 26.66 |
| P/FCF | 57.29 | 77.77 | 233.84 | — | 109.35 | 39.03 | |
Yields TTM | |||||||
| Earnings Yield | 3.63% | 3.83% | 4.34% | 3.64% | 3.93% | 5.59% | 6.15% |
| Dividend Yield | 0.19% | 0.19% | 0.23% | 0.30% | 0.26% | 0.31% | 0.21% |
| Total Yield (TY) | 3.82% | 4.02% | 4.57% | 3.94% | 4.19% | 5.90% | 6.36% |
Risk Premium [3] | |||||||
| Risk Free Rate (Rf) | 4.65% | 4.65% | 4.18% | 4.58% | 3.88% | 3.88% | 1.52% |
| Risk Prem. (TY - Rf) | -0.83% | -0.63% | 0.39% | -0.64% | 0.31% | 2.02% | 4.84% |
Growth Rates [6] | |||||||
| Sales Growth | 11.6% | 5.8% | 11.1% | 7.3% | -4.0% | 1.1% | |
| Earnings Growth [7] | -135.1% | -272.9% | -87.8% | ||||
[1] P/E uses the aggregate method over profitable constituents; P/FCF aggregates net free cash flow across all constituents (negative-FCF names reduce it); P/S uses all constituents. Ratios reflect current ETF holdings at current weights. P/FCF has no Forward column (no analyst FCF estimate).
[2] P/E (Non-GAAP) uses analyst consensus net income (adjusted basis) for all periods. The standard P/E row above uses GAAP net income.
[3] The premium above the risk free rate (US 10Y) offered by the investment. Negative premiums can indicate stretched valuations.
Show more
Top 20 Holdings for IBB
Total Weights Top 5: 32.9% | Top 10: 45.4% | Top 20: 60.7%
| Ticker | Holding | ETF Weight | Sales Weight | Earnings Weight | Fwd P/S | Fwd P/E | Fwd Sales Growth | Fwd Earnings Growth |
|---|---|---|---|---|---|---|---|---|
| Total | 76.83% | 100.00% | 100.00% | 6.2 | 27.4 | +11.6% | +16.6% | |
| Top 20 | 49.90% | 67.47% | 81.38% | 6.0 | 22.8 | +9.9% | +19.2% | |
| AMGN | Amgen | 8.65% | 13.27% | 20.01% | 5.7 | 17.6 | +2.9% | +4.4% |
| VRTX | Vertex Pharmaceuticals | 7.78% | 6.69% | 15.38% | 9.4 | 25.1 | +10.1% | +14.2% |
| GILD | Gilead Sciences | 7.00% | 11.71% | — | 5.2 | 20.9 | +6.7% | — |
| REGN | Regeneron Pharmaceuticals | 6.00% | 10.19% | 18.66% | 4.7 | 13.5 | +8.9% | +13.2% |
| ARGX | argenx | 3.50% | — | — | — | — | — | — |
| RVMD | Revolution Medicines | 2.90% | — | — | — | — | — | — |
| NTRA | Natera | 2.79% | 1.50% | — | 14.5 | — | +19.0% | — |
| BIIB | Biogen | 2.33% | 6.92% | 3.78% | 2.9 | 13.5 | +2.0% | +33.1% |
| ILMN | Illumina | 2.25% | 3.17% | 3.83% | 6.0 | 32.5 | +5.8% | +13.7% |
| ALNY | Alnylam Pharmaceuticals | 2.21% | 3.33% | 3.68% | 4.4 | 24.7 | +28.0% | +47.6% |
| INSM | Insmed | 2.19% | 0.77% | — | 12.1 | — | +62.9% | — |
| ONC | BeOne Medicines | 2.02% | — | — | — | — | — | — |
| INCY | Incyte | 1.81% | 3.92% | 7.13% | 4.0 | 16.7 | +5.2% | +156.0% |
| UTHR | United Therapeutics | 1.68% | 2.14% | 5.84% | 6.7 | 16.4 | +10.1% | +13.8% |
| MRNA | Moderna | 1.51% | 1.27% | — | 10.0 | — | +19.5% | — |
| ROIV | Roivant Sciences | 1.40% | 0.00% | — | 91.0 | — | +772.9% | — |
| NBIX | Neurocrine Biosciences | 1.22% | 2.24% | 3.07% | 3.9 | 18.6 | +16.4% | +31.8% |
| GMAB | Genmab | 1.20% | — | — | — | — | — | — |
| ASND | Ascendis Pharma | 1.19% | — | — | — | — | — | — |
| BBIO | BridgeBio Pharma | 1.08% | 0.34% | — | 11.9 | — | +66.9% | — |
[2] Forward P/S and P/E ratios use consensus sales and earnings for the 12 months ending 8/31/27. Individual constituent FY1 and FY2 consensus figures adjusted to align with 8/31/27.
[3] Forward Sales and Non-GAAP Earnings Growth are calculated as next fiscal year (FY2) consensus growth over current fiscal year (FY1) consensus. They are not derived from the forward P/S and P/E multiples shown.
Performance for IBB Top Holdings
| Ticker | Holding | Weight | Mkt Price8/10 | 1D Rtn | 1M Rtn | YTD Rtn | 1Y Rtn | 3Y Rtn | 5Y Rtn | 10Y Rtn |
|---|---|---|---|---|---|---|---|---|---|---|
| IBB | iShares Biotechnology ETF | 100.00% | 200.02 | 1.2% | 4.1% | 18.6% | 51.8% | 56.9% | 20.7% | 110.1% |
| AMGN | Amgen | 8.65% | 417.20 | 1.5% | 14.8% | 29.3% | 49.1% | 74.3% | 114.1% | 227.4% |
| VRTX | Vertex Pharmaceuticals | 7.78% | 523.91 | 5.6% | 7.9% | 15.6% | 42.9% | 49.7% | 168.3% | 416.0% |
| GILD | Gilead Sciences | 7.00% | 133.06 | -0.1% | 2.5% | 9.7% | 14.3% | 83.6% | 128.7% | 138.0% |
| REGN | Regeneron Pharmaceuticals | 6.00% | 808.05 | 3.0% | 21.6% | 5.0% | 44.3% | 1.0% | 33.9% | 93.3% |
| ARGX | argenx | 3.50% | 866.11 | 0.1% | -1.3% | 3.0% | 30.9% | 75.5% | 176.6% | |
| RVMD | Revolution Medicines | 2.90% | 206.97 | 0.9% | 10.8% | 159.8% | 491.3% | 590.1% | 669.4% | |
| NTRA | Natera | 2.79% | 318.35 | -1.2% | 17.9% | 39.0% | 109.5% | 466.4% | 210.4% | 2,794.1% |
| BIIB | Biogen | 2.33% | 207.13 | -0.4% | 4.0% | 17.7% | 58.5% | -24.3% | -38.9% | -28.3% |
| ILMN | Illumina | 2.25% | 191.79 | 2.0% | 0.8% | 46.2% | 102.8% | 9.3% | -60.7% | 18.2% |
| ALNY | Alnylam Pharmaceuticals | 2.21% | 216.98 | -1.0% | -27.4% | -45.4% | -50.6% | 16.8% | 7.0% | 192.9% |
| INSM | Insmed | 2.19% | 134.75 | 2.8% | 16.6% | -22.6% | 23.0% | 500.8% | 453.2% | 1,031.4% |
| ONC | BeOne Medicines | 2.02% | 359.00 | 3.1% | 20.2% | 18.2% | 24.6% | 81.6% | 28.3% | 1,175.3% |
| INCY | Incyte | 1.81% | 121.55 | 0.8% | 4.1% | 23.1% | 55.1% | 84.4% | 66.7% | 50.0% |
| UTHR | United Therapeutics | 1.68% | 529.66 | -1.7% | -3.2% | 8.7% | 75.7% | 122.7% | 161.9% | 323.1% |
| MRNA | Moderna | 1.51% | 59.81 | 1.1% | -12.4% | 102.8% | 129.0% | -41.1% | -84.5% | |
| ROIV | Roivant Sciences | 1.40% | 35.78 | -1.5% | -0.5% | 64.9% | 211.4% | 209.2% | 260.0% | |
| NBIX | Neurocrine Biosciences | 1.22% | 164.92 | 0.9% | -6.9% | 16.3% | 31.9% | 56.7% | 91.4% | 240.9% |
| GMAB | Genmab | 1.20% | 30.87 | -1.2% | 6.4% | 0.2% | 44.1% | -17.5% | -31.2% | 75.6% |
| ASND | Ascendis Pharma | 1.19% | 255.62 | 0.1% | -5.5% | 19.9% | 33.5% | 176.9% | 109.3% | 1,591.7% |
| BBIO | BridgeBio Pharma | 1.08% | 84.67 | 0.2% | -1.4% | 10.7% | 81.8% | 172.5% | 62.4% |
Guidance Updates for IBB Top Holdings
| Ticker | Company | Earnings Date | Guidance Metric | Midpoint Value | % Change | Guidance Change | |
|---|---|---|---|---|---|---|---|
| ALNY_7302026 | ALNY | Alnylam Pharmaceuticals | 7/30/2026 | 2026 Net revenues from collaborations and royalties | 600.00 Mil | 33.3% | RaisedRaised Prior Guidance of 450.00 Mil for 2026 |
| INCY_7282026 | INCY | Incyte | 7/28/2026 | 2026 Total net sales | 5.20 Bil | 7.0% | RaisedRaised Prior Guidance of 4.86 Bil for 2026 |
| INSM_8062026 | INSM | Insmed | 8/6/2026 | 2026 BRINSUPRI Revenue | 1.32 Bil | 32.5% | RaisedRaised Prior Guidance of 1.00 Bil for 2026 |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IBB Return | 1% | -14% | 4% | -2% | 28% | 17% | 32% |
| Peers Return | 28% | -8% | 33% | 14% | 34% | 44% | 247% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 107% |
Monthly Win Rates [3] | |||||||
| IBB Win Rate | 42% | 50% | 58% | 58% | 58% | 62% | |
| Peers Win Rate | 62% | 48% | 57% | 55% | 68% | 70% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| IBB Max Drawdown | -17% | -31% | -18% | -12% | -21% | -10% | |
| Peers Max Drawdown | -22% | -38% | -19% | -20% | -28% | -20% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SMH, SOXX, XBI, ITA, XOP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/10/2026 (YTD)
Sharpe Ratios Compared
One measure of reward vs. risk is a Sharpe ratio. A higher ratio indicates better risk-adjusted returns. Most funds have Sharpe ratios < 1.0.
Results as of 7312026.How Low Can It Go
| Event | IBB | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -19.2% | -18.8% |
| % Gain to Breakeven | 23.7% | 23.1% |
| Time to Breakeven | 129 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -12.8% | -9.5% |
| % Gain to Breakeven | 14.7% | 10.5% |
| Time to Breakeven | 47 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -30.5% | -24.5% |
| % Gain to Breakeven | 43.8% | 32.4% |
| Time to Breakeven | 1205 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -23.6% | -33.7% |
| % Gain to Breakeven | 30.8% | 50.9% |
| Time to Breakeven | 32 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -26.1% | -19.2% |
| % Gain to Breakeven | 35.3% | 23.8% |
| Time to Breakeven | 357 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -16.3% | -3.7% |
| % Gain to Breakeven | 19.5% | 3.9% |
| Time to Breakeven | 116 days | 6 days |
In The Past
iShares Biotechnology ETF's stock fell -19.2% during the 2025 US Tariff Shock. Such a loss loss requires a 23.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | IBB | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -30.5% | -24.5% |
| % Gain to Breakeven | 43.8% | 32.4% |
| Time to Breakeven | 1205 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -23.6% | -33.7% |
| % Gain to Breakeven | 30.8% | 50.9% |
| Time to Breakeven | 32 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -26.1% | -19.2% |
| % Gain to Breakeven | 35.3% | 23.8% |
| Time to Breakeven | 357 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -34.3% | -12.2% |
| % Gain to Breakeven | 52.3% | 13.9% |
| Time to Breakeven | 1411 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -22.3% | -17.9% |
| % Gain to Breakeven | 28.7% | 21.8% |
| Time to Breakeven | 155 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -29.3% | -53.4% |
| % Gain to Breakeven | 41.5% | 114.4% |
| Time to Breakeven | 196 days | 1085 days |
In The Past
iShares Biotechnology ETF's stock fell -19.2% during the 2025 US Tariff Shock. Such a loss loss requires a 23.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Current Dip Buy Opportunities Across ETFs
ETFs currently down 5% or more from trailing 6M peaks.
| Ticker | Name | Dip % | Mkt Price | Price Date | Peak Price | Peak Date | # Days |
|---|---|---|---|---|---|---|---|
| IEMG | iShares Core MSCI Emerging Markets ETF | -7.5% | 79.56 | 8102026 | 86.00 | 6222026 | 49 |
| EEM | iShares MSCI Emerging Markets ETF | -8.5% | 65.17 | 8102026 | 71.21 | 6222026 | 49 |
| ASHR | Xtrackers Harvest CSI 300 China A-Shares ETF | -6.3% | 34.96 | 8102026 | 37.30 | 6222026 | 49 |
| EWY | iShares MSCI South Korea ETF | -25.6% | 163.12 | 8102026 | 219.20 | 6212026 | 50 |
| EWZ | iShares MSCI Brazil ETF | -15.7% | 35.19 | 8102026 | 41.73 | 4142026 | 118 |
| FXI | iShares China Large-Cap ETF | -7.7% | 36.49 | 8102026 | 39.53 | 2102026 | 181 |
| ILF | iShares Latin America 40 ETF | -9.4% | 34.52 | 8102026 | 38.10 | 4142026 | 118 |
| KWEB | KraneShares CSI China Internet ETF | -15.2% | 29.12 | 8102026 | 34.34 | 2092026 | 182 |
| MTUM | iShares MSCI USA Momentum Factor ETF | -11.0% | 307.32 | 8102026 | 345.22 | 6222026 | 49 |
| SPMO | Invesco S&P 500 Momentum ETF | -8.0% | 148.70 | 8102026 | 161.66 | 6222026 | 49 |
| URA | Global X Uranium ETF | -23.8% | 44.38 | 8102026 | 58.26 | 5062026 | 96 |
| BOTZ | Global X Funds Global X Robotics & Artificial Intelligence ETF | -10.1% | 37.42 | 8102026 | 41.63 | 5132026 | 89 |
| ROBO | ROBO Global Robotics & Automation Index ETF | -7.6% | 83.46 | 8102026 | 90.34 | 6022026 | 69 |
| LIT | Global X Lithium & Battery Tech ETF | -18.4% | 74.74 | 8102026 | 91.62 | 5112026 | 91 |
| ICLN | iShares Global Clean Energy ETF | -23.9% | 18.08 | 8102026 | 23.75 | 6022026 | 69 |
| ARKQ | ARK Autonomous Technology & Robotics ETF | -11.1% | 127.89 | 8102026 | 143.82 | 5282026 | 74 |
| ARKX | ARK Space & Defense Innovation ETF | -8.8% | 34.41 | 8102026 | 37.74 | 5282026 | 74 |
| NASA | Tema Space Innovators ETF | -39.4% | 25.39 | 8102026 | 41.89 | 5272026 | 75 |
| XOVR | EntrepreneurShares Series Trust ERShares Private-Public Crossover ETF | -5.2% | 20.22 | 8102026 | 21.34 | 7062026 | 35 |
| AGIX | KraneShares Artificial Intelligence ETF | -8.7% | 45.09 | 8102026 | 49.40 | 6012026 | 70 |
| XLK | State Street Technology Select Sector SPDR ETF | -6.0% | 186.32 | 8102026 | 198.21 | 6022026 | 69 |
| XLC | State Street Communication Services Select Sector SPDR ETF | -6.1% | 111.83 | 8102026 | 119.10 | 4192026 | 113 |
| XLP | State Street Consumer Staples Select Sector SPDR ETF | -5.1% | 84.95 | 8102026 | 89.51 | 3012026 | 162 |
| XLU | State Street Utilities Select Sector SPDR ETF | -9.0% | 43.13 | 8102026 | 47.40 | 3012026 | 162 |
| SMH | VanEck Semiconductor ETF | -14.9% | 569.41 | 8102026 | 668.91 | 6222026 | 49 |
| SOXX | iShares Semiconductor ETF | -19.2% | 529.39 | 8102026 | 655.01 | 6222026 | 49 |
| XOP | State Street SPDR S&P Oil & Gas Exploration & Production ETF | -6.5% | 175.93 | 8102026 | 188.18 | 3292026 | 134 |
| MISL | First Trust Indxx Aerospace & Defense ETF | -6.3% | 47.49 | 8102026 | 50.66 | 3022026 | 161 |
| RING | iShares MSCI Global Gold Miners ETF | -21.2% | 78.38 | 8102026 | 99.42 | 3012026 | 162 |
| SOXQ | Invesco PHLX Semiconductor ETF | -18.0% | 94.44 | 8102026 | 115.11 | 6222026 | 49 |
| TLT | iShares 20+ Year Treasury Bond ETF | -7.9% | 82.06 | 8102026 | 89.15 | 3012026 | 162 |
| VGLT | Vanguard Long-Term Treasury ETF | -6.8% | 52.68 | 8102026 | 56.53 | 3012026 | 162 |
| SPTL | State Street SPDR Portfolio Long Term Treasury ETF | -7.2% | 25.05 | 8102026 | 26.99 | 3012026 | 162 |
| TLH | iShares 10-20 Year Treasury Bond ETF | -6.5% | 96.39 | 8102026 | 103.08 | 3012026 | 162 |
| EDV | Vanguard World Funds Extended Duration ETF | -11.6% | 59.57 | 8102026 | 67.42 | 3012026 | 162 |
| SPLB | State Street SPDR Portfolio Long Term Corporate Bond ETF | -5.3% | 21.35 | 8102026 | 22.55 | 2192026 | 172 |
| IGLB | iShares 10+ Year Investment Grade Corporate Bond ETF | -5.0% | 47.83 | 8102026 | 50.37 | 2172026 | 174 |
| PDBC | Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF | -5.7% | 17.83 | 8102026 | 18.91 | 5122026 | 90 |
| DBC | Invesco DB Commodity Index Tracking Fund | -5.6% | 29.93 | 8102026 | 31.69 | 5122026 | 90 |
| COMT | iShares GSCI Commodity Dynamic Roll Strategy ETF | -8.0% | 33.59 | 8102026 | 36.53 | 5192026 | 83 |
| GSG | iShares GSCI Commodity | -5.8% | 30.01 | 8102026 | 31.85 | 3182026 | 145 |
| BCI | abrdn Bloomberg All Commodity Strategy K-1 Free ETF | -5.5% | 24.49 | 8102026 | 25.91 | 5122026 | 90 |
| GLD | SPDR Gold Trust | -17.8% | 402.54 | 8102026 | 490.00 | 3022026 | 161 |
| IAU | iShares Gold Trust | -17.8% | 82.51 | 8102026 | 100.38 | 3022026 | 161 |
| GLDM | SPDR Gold MiniShares Trust | -17.7% | 86.81 | 8102026 | 105.54 | 3022026 | 161 |
| SGOL | ETFS Physical Swiss Gold Shares | -12.1% | 44.66 | 8102026 | 50.81 | 3022026 | 161 |
| BAR | Direxion Daily Gold Bull 3X Shares | -15.6% | 44.34 | 8102026 | 52.53 | 3022026 | 161 |
| SLV | iShares Silver Trust | -30.1% | 59.41 | 8102026 | 84.99 | 3012026 | 162 |
| SIVR | ETFS Physical Silver Shares Trust ETF | -6.6% | 83.39 | 8102026 | 89.26 | 3012026 | 162 |
| PPLT | ETFS Physical Platinum Shares | -25.9% | 15.91 | 8102026 | 21.47 | 3012026 | 162 |
| CPER | United States Copper Index Fund ETV | -9.6% | 33.33 | 8102026 | 36.88 | 3012026 | 162 |
| PALL | ETFS Physical Palladium Shares | -22.8% | 25.11 | 8102026 | 32.54 | 2242026 | 167 |
| USO | United States Oil Fund LP | -17.7% | 125.92 | 8102026 | 152.96 | 5192026 | 83 |
| UNG | United States Natural Gas Fund LP | -22.2% | 10.14 | 8102026 | 13.04 | 3122026 | 151 |
| BNO | United States Brent Oil Fund LP ETV | -7.1% | 55.85 | 8102026 | 60.13 | 5042026 | 98 |
| IBIT | iShares Bitcoin Trust ETF | -22.0% | 36.23 | 8102026 | 46.47 | 5112026 | 91 |
| FBTC | Fidelity Wise Origin Bitcoin Fund | -22.0% | 55.65 | 8102026 | 71.35 | 5112026 | 91 |
| ETHA | iShares Ethereum Trust ETF | -23.1% | 14.14 | 8102026 | 18.38 | 4192026 | 113 |
ETF Fund Flows
Largest fund inflows and outflows across ETFs, with the asset-allocation rotation they imply.
Asset allocation rotation · Past month
- Equity ETFs drew the largest net inflows (+$57.8B), followed by Bond (+$13.7B), with every major asset class in net inflows.
- Within the mix, money rotated into US Large Cap Core (+$15.6B) and out of Thematic (−$3.2B).
- Relative to fund size, BFLX drew the largest inflow (+55.7% of AUM) and FTXL the largest outflow (−49.7%).
| # | Ticker | Name | Net flow | % of AUM |
|---|---|---|---|---|
| 1 | VOO | Vanguard S&P 500 ETF | +$11.9B | +1.2% |
| 2 | QQQ | Invesco QQQ Trust, Series 1 | +$11.24B | +2.4% |
| 3 | SPY | State Street SPDR S&P 500 ETF | +$10.94B | +1.4% |
| 4 | EWY | iShares MSCI South Korea ETF | +$6.01B | +25.7% |
| 5 | SPYM | State Street SPDR Portfolio S&P 500 ETF | +$5.46B | +3.4% |
| 6 | DRAM | Roundhill Memory ETF | +$3.87B | +16.2% |
| 7 | SGOV | iShares 0-3 Month Treasury Bond ETF | +$3.85B | +3.9% |
| 8 | TLT | iShares 20+ Year Treasury Bond ETF | +$3.32B | +7.8% |
| 9 | QQQM | Invesco NASDAQ 100 ETF | +$3.26B | +3.3% |
| 10 | SCHD | Schwab U.S. Dividend Equity ETF | +$3.15B | +3.1% |
| # | Ticker | Name | Net flow | % of AUM |
|---|---|---|---|---|
| 1 | IVV | iShares Core S&P 500 ETF | -$12.44B | -1.4% |
| 2 | IEF | iShares 7-10 Year Treasury Bond ETF | -$3.67B | -7.8% |
| 3 | IWM | iShares Russell 2000 ETF | -$2.72B | -3.4% |
| 4 | LQD | iShares iBoxx $ Investment Grade Corporate Bond ETF | -$2.48B | -7.4% |
| 5 | ARKK | ARK Innovation ETF | -$2.34B | -39.4% |
| 6 | IQMM | ProShares - GENIUS Money Market ETF | -$2.22B | -12.4% |
| 7 | IWF | iShares Russell 1000 Growth ETF | -$1.06B | -0.9% |
| 8 | IWD | iShares Russell 1000 Value ETF | -$1.05B | -1.3% |
| 9 | VO | Vanguard Morningstar Mid-Cap ETF | -$1.01B | -0.9% |
| 10 | IWR | iShares Russell Mid-Cap ETF | -$944M | -1.7% |
Largest ETF fund flows across ~2598 funds (min AUM $100M). Net creations/redemptions; leveraged & inverse ETFs excluded. A ⚠ marks a day excluded as a suspected data error.
About IBB
| Holdings Count: 247Expense Ratio: 0.44%Inception Date: 2001-02-05 | iShares Biotechnology ETFThe iShares Biotechnology ETF (IBB) is designed to mirror the investment performance of a specific market index. This index comprises publicly traded stocks from companies operating within the U.S. biotechnology sector.Asset Class: Equity | ETF Website |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| IBB ETF Holds Fewer Bets Than You Think | 07/15/2026 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Profile
| Median | |
|---|---|
| Name | |
| Asset Class | - |
| AUM ($ Bil) | 12.6 |
| Expense Ratio | 0.35% |
| 10-D Avg Volume (Mil) | 6.25 |
| Latest Day Volume (Mil) | 5.86 |
| Holdings Count | 50 |
| Inception Date | - |
Fundamentals
| Median | |
|---|---|
| Name | |
| Net Asset Value | - |
| Premium/Discount | 0.7% |
| Distribution Yield | 0.2% |
| Sales Yield | 10.4% |
| Earnings Yield | 2.2% |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.